Your browser doesn't support javascript.
loading
Neurological manifestations of neurofibromatosis type 1: our experience. / Manifestaciones neurológicas en neurofibromatosis tipo 1. Nuestra experiencia.
Sánchez Marco, S B; López Pisón, J; Calvo Escribano, C; González Viejo, I; Miramar Gallart, M D; Samper Villagrasa, P.
Affiliation
  • Sánchez Marco SB; Unidad de Neurología Pediátrica, Servicio de Pediatría, Hospital Infantil Universitario Miguel Servet, Zaragoza, España. Electronic address: sbsanchez@salud.aragon.es.
  • López Pisón J; Unidad de Neurología Pediátrica, Servicio de Pediatría, Hospital Infantil Universitario Miguel Servet, Zaragoza, España.
  • Calvo Escribano C; Unidad de Oncohematología Pediátrica, Servicio de Pediatría, Hospital Infantil Universitario Miguel Servet, Zaragoza, España.
  • González Viejo I; Servicio de Oftalmología, Hospital Infantil Universitario Miguel Servet, Hospital Infantil Universitario Miguel Servet, Zaragoza, España.
  • Miramar Gallart MD; Servicio de Genética Clínica, Hospital Universitario Miguel Servet, Zaragoza, España.
  • Samper Villagrasa P; Departamento de Pediatría, Radiología y Medicina Física, Facultad de Medicina de Zaragoza, Universidad de Zaragoza, Zaragoza, España.
Neurologia (Engl Ed) ; 2019 Jul 17.
Article in En, Es | MEDLINE | ID: mdl-31326214
ABSTRACT

INTRODUCTION:

Neurofibromatosis type 1 (NF1) is a progressive multisystem disorder following an autosomal dominant inheritance pattern that presents with multiple neurological manifestations.

METHODS:

We reviewed medical histories of patients with NF1 followed up at our hospital's paediatric neurology department from May 1990 to 31 December 2018. We collected data on neurological symptoms.

RESULTS:

A total of 128 patients with NF1 were identified. Mean age (SD) at NF1 diagnosis was 4.43 (3.38) years (range, 0.5-14.5 years). There was a slight female predominance (53.1%). Macrocephaly (head circumference over 2 SDs above average for age) was present in 37.5% of cases. Attention-deficit/hyperactivity disorder was recorded in 28.9% of patients (37) combined type in 20 patients, predominantly inattentive in 15, and predominantly impulsive/hyperactive in 2. Other manifestations included headache (18.6%), cognitive impairment (7.8%), motor deficit (6.2%), and epilepsy (4.68%). Brain MRI was performed in 85 patients, revealing T2-weighted hyperintensities in the basal ganglia and/or cerebellum in 60 patients (70.5%), Chiari malformation type 1 in 4 cases, and arachnoid cysts in 3. Optic nerve gliomas were identified by MRI in 22 patients (25.8%). Other MRI findings included plexiform neurofibromas (9.3%) and central nervous system gliomas (3.1%).

CONCLUSIONS:

The neurological manifestations identified in our sample are consistent with those reported in the literature. Effective transfer strategies from paediatric neurology departments and subsequent clinical follow-up by adult neurology departments are needed to prevent loss to follow-up in adulthood.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En / Es Journal: Neurologia (Engl Ed) Year: 2019 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En / Es Journal: Neurologia (Engl Ed) Year: 2019 Type: Article